carmot glp-1 Therapeutics Roche's GLP1/GIP drug sees 22.5%

To investigate the specific role of BBS5 in metabolic disease, we used a Bbs5 / mouse (7) maintained on a homogeneous C57BL/6J background born from heterozygous parents

Side-effect profiles are similar but not identical

Diabetes Care (2020) 43(6):13525

Alexa Canciello, a 23-year-old with autism, lives with her parents outside Pittsburgh and had a weight problem for years because her brain doesnt know when to shut off the hunger drive, her father Rich said

These side effects are most common in the first days and weeks after beginning GLP-1 therapy or after increasing dosage, but for some patients, they may persist for longer